What's New


04.04.2008
AERS for Prescribed COX-II, Celebrex and Vioxx
This Report provides detailed analysis and information concerning the adverse events reported against the prescribed COX-II inhibitors Bextra, Celebrex and Vioxx.
04.04.2008
Disease and Therapeutic Information Report: Multiple Sclerosis
This report provides a scientific documentation on Multiple Sclerosis covering the history, demographics, diagnosis, pathology & progression of the disease along with current and available treatment options, healthy living and support information
04.04.2008
Analysis on the FDA Adverse Event Report System (AERS) for Chantix
From brittle hair to stomach ulcer and problems with conception, the effects of smoking are numerous and often deadly.
08.04.2008
Social Media and Market Intelligence Report: Multiple Sclerosis
Consumer sentiment analysis, analysis of key performance drivers, brand popularity analysis, brand engagement metrics analysis and more for Avonex, Betaseron, Copaxone, Rebif, Tysabri and Novantrone in this consumer market intelligence report for Multiple Sclerosis.
04.04.2008
AERS for Bisphosphonates
In an era where drugs are progressively being used for the treatment of multiple disease areas, a group of drugs termed as Bisphosphonates are following a similar contour rather than demarcating themselves as an exception to this rule. The Bisphosphonates assemblage of Actonel, Boniva, Fosamax and Zometa entered the drug market to serve the purpose of treating Osteoporosis as well as multiple indications across the globe.
07.04.2008
Disease and Therapeutic Information Report: Crohn’s Disease
This report provides a scientific documentation on Crohn’s I covering the history, demographics, diagnosis, pathology & progression of the disease along with current and available treatment options, healthy living and disease support information.
04.04.2008
Thiazolidone derivatives for Type II Diabetes Mellitus- An analysis of the adverse event report system
The following analysis tries to outline the extravagant use of Thiazolidone derivatives namely Avandia, Actos, Avandamet and Avandaryl terms of real-time numbers recorded in the FDA AERS database so as to able to delineate the number of cases, adverse events, side effects and adverse reactions for these drugs along with their respective outcomes
05.04.2008
Social Media and Market Intelligence Report: Hepatitis C
Consumer sentiment analysis, analysis of key performance drivers, brand popularity analysis, brand engagement metrics analysis and more for Pegasys, Peg-Intron and Infergen in this consumer market intelligence report for Hepatitis C.
04.04.2008
AERS analysis of the Atypical Antipsychotics for the period 2004Q1 to 2007Q4
The report provides detailed analysis and information concerning the adverse events reported against the Atypical Antipsychotics’ Abilify, Geodon, Risperdal, Seroquel and Zyprexa. An in-depth analysis of the number of cases, reports, adverse reactions and outcomes with respect to this drug class have been carried out in the report with supplemental data in the form of the key market parameters such as sales and dispensed prescripts, dosage and modes of administration and exhaustive information on drug profiles.
04.04.2008
AERS analysis for the Statins blockbusters Baycol, Crestor and Lipitor (2004Q1 – 2006Q4)
The pharmaceutical market is fiercely competitive, yet cholesterol therapies have maintained their dominant position for over two decades. While the overwhelming supremacy of cholesterol therapies Baycol, Crestor and Lipitor is set to continue, the side effects resulting from the consumption of these medications are being increasingly revealed and brought to the vanguard of discussions involving these drugs.
 


Enter your e-mail id for our daily newsletter subscription

   
Overview
Primus Analytics is a knowledge service provider in the areas of business and market research for the pharmaceutical and biotechnology domain. At Primus, we thrive to build long-term strategic relationships with our clients revolving around the concept of value exchange. For us, establishing a relationship that is geared towards long-term success is as much an art as it is a science.

Our Focus

Healthcare domain is highly characterized by factors like Time to Market, Data Sensitivity and Accuracy, Customer Consciousness, Regulatory Requirements and Business Intelligence. In order to offer the best value in such a highly competitive environment, we are not only focused on aligning with high quality standards, but also
  • Innovating continuously to keep up-to-date with the ever-changing media landscape
  • Working faster and smarter
  • Using in-house technology team to assist with tools that increase our productivity levels

Why Work With Us

Outsourcing to us is more than just cost-savings for you. Firstly, we help you to respond quickly to changing market needs by allowing you to focus on your core competencies. Secondly, with the zeal for knowledge as our driving force, our unique research model permits us to continually and consistently deliver on our dual values of precision and quality. Finally, we help reduce your costs in this area by 30-50% depending on your demography.

We look forward to share with you on how we deliver the following KPIs: Reduced Time to Market, Lower Total Cost of Ownership, Product Standards and Quality, Innovation